Want to Retire on $500,000? 3 Stocks to Buy and Never Sell

The article highlights three high-yield income stocks—Ares Capital at 10.6%, Energy Transfer at roughly 7.2%, and Pfizer at more than 6.8%—as potential retirement portfolio candidates. Ares Capital is said to have 67 straight quarters of stable or rising dividends, Energy Transfer expects 3% to 5% annual distribution growth, and Pfizer has raised its dividend for 16 consecutive years despite patent-cliff pressure. The piece is broadly constructive on dividend durability and cash generation, but it is mainly opinion/analysis rather than new company-specific news.

Analysis

The common thread here is not simply “high yield,” but the durability of cash flows in three very different regimes. ARCC is the cleanest expression of the idea because its diversified credit book and spillover income reduce the usual BDC reflexivity risk: if credit tightens, it has a reserve buffer before the dividend is at risk. That makes it more resilient than the market tends to price for, especially if rates drift lower and refinancing stress eases across lower-quality private borrowers.

ET is the most interesting second-order beneficiary because the AI/data-center trade is usually thought of as semis + power utilities, not midstream. The real upside is that gas-pipeline takeaway becomes a constraint-release valve for compute growth; if data-center buildouts accelerate, gas transportation and gathering volumes can rise even without a dramatic commodity price move. The main risk is political/regulatory friction or a slowdown in capex decisions by hyperscalers, which would show up over months rather than days.

PFE is the most controversial: the dividend is not the issue, the earnings bridge is. The market is still pricing the company through the rear-view mirror of pandemic-era revenue, so any rerating depends on whether pipeline execution can offset patent erosion before the cliff becomes visible in consensus numbers. The contrarian point is that if management hits even modest post-cliff growth, the stock’s downside may be capped by yield-oriented capital, while upside comes from multiple expansion off a depressed base.

Key Decisions for Investors

• Long ARCC vs. high-yield credit proxies for the next 6-12 months: attractive carry with lower drawdown risk if credit conditions stabilize; trim if non-accruals start moving materially higher.
• Add ET on pullbacks as a 6-18 month thematic AI-infrastructure hedge: the market is underappreciating gas takeaway demand from data centers; stop if hyperscaler capex guidance rolls over.
• Buy PFE only as a yield-supported value position, ideally paired against a stronger large-cap pharma basket over 12 months: limited near-term catalyst, but favorable skew if pipeline delivery beats low expectations.
• Pair long ET / short ORCL or a data-center capex-sensitive basket as a relative-value trade if you want exposure to AI infrastructure without paying semis multiples; works best if gas demand from compute outpaces equity-market enthusiasm.
• Avoid chasing all three at once: build a barbell of ARCC + ET for cash generation, then use PFE only as a smaller position size until patent-cliff execution becomes visible in quarterly data.